Ezetimibe added to statin therapy reduces LDL-C and improves goal attainment in patients with diabetes, metabolic syndrome, or metabolic dyslipidemia

被引：0

作者：

McBride, P

Denke, MA

Pearson, T

Battisti, WP

Brady, WE

Palmisano, J

机构：

[1] Univ Wisconsin, Sch Med, Cardiovasc Dept, Madison, WI USA

[2] Univ Texas Hlth Sci Ctr San Antonio, Kerrville, TX USA

[3] Univ Rochester, Sch Med & Dent, Dept Community & Prevent Med, Rochester, NY USA

[4] Merck & Co Inc, Clin Dev, West Point, PA USA

来源：

DIABETOLOGIA | 2004年 / 47卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

559

引用

页码：A204 / A205

页数：2

共 50 条

[31] Projected LDL-C reduction and goal attainment by switching patients to dual inhibition therapy (Ezetimibe/Simvastatin 10/20mg) in Spain
Nocea, G
Davies, G
Caloto, MT
Alemao, E
Yin, D
Cook, J
VALUE IN HEALTH, 2005, 8 (06) : A104 - A104
[32] RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale
Takeshi Inazawa
Kentaro Sakamoto
Takahide Kohro
Raisuke Iijima
Toru Kitazawa
Tsutomu Hirano
Mitsunobu Kawamura
Motoki Tagami
Akira Tanaka
Yasumichi Mori
Tsutomu Yamazaki
Teruo Shiba
Lipids in Health and Disease, 12
[33] ACHIEVING THE LDL-C GOAL IN INDIAN PATIENTS OF ACUTE CORONARY SYNDROME WITH HIGH INTENSITY STATIN
Sawhney, J.
Vanani, J. G.
Madan, K.
Sharma, M. K.
Tyagi, K.
Kandpal, B.
Mehta, A.
ATHEROSCLEROSIS, 2022, 355 : E189 - E189
[34] Individualized initiation of statin therapy determined by baseline LDL-C: Are you more likely to achieve goal LDL-C?
Clem, James R.
Strain, Joe D.
Farver, Debra K.
RISK MANAGEMENT AND HEALTHCARE POLICY, 2010, 3 : 1 - 11
[35] EVALUATION OF LDL-C REDUCTIONS BY SIRNA TREATMENT WITH INCLISIRAN IN PATIENTS WITH DIABETES MELLITUS, METABOLIC SYNDROME OR NEITHER
Wright, R. Scott
Kallend, David
Ray, Kausik Kumar
Leiter, Lawrence
Koenig, Wolfgang
Raal, Frederick
Wijngaard, Peter
Kastelein, John J. P.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 2005 - 2005
[36] Evaluation of LDL-C reductions by siRNA treatment with inclisiran in patients with diabetes mellitus, metabolic syndrome or neither
Wright, R. Scott
Kallend, David
Ray, Kausik K.
Leiter, Lawrence
Koenig, Wolfgang
Raal, Frederick
Wijngaard, Peter
Kastelein, John J. P.
EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (SUPPL G)
[37] Evaluation of LDL-C reductions by siRNA treatment with inclisiran in patients with diabetes mellitus, metabolic syndrome or neither
Wright, R. Scott
Kallend, David
Ray, Kausik K.
Leiter, Lawrence
Koenig, Wolfgang
Raal, Frederick
Wijngaard, Peter
Kastelein, John J. P.
EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (0G)
[38] Percent LDL-C reduction & NCEP-III goal attainment with ezetimibe/simvastatin vs atorvastatin titration in chd/diabetic patients not at goal
Vieira, J. L.
Davies, G. M.
Alemao, E.
Yin, D.
Cook, J.
Moriguchi, E.
ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 557 - 557
[39] Attainment of Single And Dual Treatment Levels for LDL-C and Non-HDL-C, Apo B or hs-CRP in Patients with Metabolic Syndrome: Ezetimibe/Simvastatin Versus Atorvastatin
Ballantyne, Christie M.
Grundy, Scott M.
Hsueh, Willa A.
Parving, Hans-Henrik
Robinson, Jennifer G.
Rosen, Jeffrey B.
Lin, Jianxin
Lowe, Robert S.
Shah, Arvind K.
Tomassini, Joanne E.
Tershakovec, Andrew M.
DIABETES, 2009, 58 : A174 - A174
[40] Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in CHD patients with hypercholesterolemia
Farnier, M
Volpe, M
Massaad, R
Davies, M
Allen, C
ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (01) : 107 - 107

← 1 2 3 4 5 →